Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma

John P. Leonard, Kathryn S. Kolibaba, James A. Reeves, Anil Tulpule, Ian W. Flinn, Tatjana Kolevska, Robert Robles, Christopher R. Flowers, Robert Collins, Nicholas J. DiBella, Steven Papish, Parameswaran Venugopal, Andrew Horodner, Amir Tabatabai, Julio Hajdenberg, Jaehong Park, Rachel Neuwirth, George Mulligan, Kaveri Suryanarayan, Dixie Lee Esseltine & 1 others Sven De Vos

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP (P = .611). Two-year PFS rateswere 77.6%with R-CHOP and 82.0%with VR-CHOP; they were 65.1% versus 72.4%in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade $ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.

Original languageEnglish (US)
Pages (from-to)3538-3546
Number of pages9
JournalJournal of Clinical Oncology
Volume35
Issue number31
DOIs
StatePublished - Nov 1 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Disease-Free Survival
Bortezomib
Leukopenia
Vincristine
Prednisone
Neutropenia
Thrombocytopenia
Doxorubicin
Cyclophosphamide
Anemia
Survival Rate
Immunohistochemistry
Safety
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Leonard, John P. ; Kolibaba, Kathryn S. ; Reeves, James A. ; Tulpule, Anil ; Flinn, Ian W. ; Kolevska, Tatjana ; Robles, Robert ; Flowers, Christopher R. ; Collins, Robert ; DiBella, Nicholas J. ; Papish, Steven ; Venugopal, Parameswaran ; Horodner, Andrew ; Tabatabai, Amir ; Hajdenberg, Julio ; Park, Jaehong ; Neuwirth, Rachel ; Mulligan, George ; Suryanarayan, Kaveri ; Esseltine, Dixie Lee ; De Vos, Sven. / Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 31. pp. 3538-3546.
@article{0d62892e960749fa845c4e9d6c1f8388,
title = "Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma",
abstract = "Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25{\%} (R-CHOP) and 18{\%} (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90{\%} CI, 0.43 to 1.24) with VR-CHOP (P = .611). Two-year PFS rateswere 77.6{\%}with R-CHOP and 82.0{\%}with VR-CHOP; they were 65.1{\%} versus 72.4{\%}in patients with high-intermediate/high IPI (HR, 0.67; 90{\%} CI, 0.34 to 1.29), and 90.0{\%} versus 88.9{\%} (HR, 0.85; 90{\%} CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98{\%} and 96{\%}, respectively. The overall survival HR was 0.75 (90{\%} CI, 0.38 to 1.45); 2-year survival rates were 88.4{\%} and 93.0{\%}, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade $ 3 adverse events included neutropenia (53{\%} v 49{\%}), thrombocytopenia (13{\%} v 29{\%}), anemia (7{\%} v 15{\%}), leukopenia (26{\%} v 25{\%}), and neuropathy (1{\%} v 5{\%}). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.",
author = "Leonard, {John P.} and Kolibaba, {Kathryn S.} and Reeves, {James A.} and Anil Tulpule and Flinn, {Ian W.} and Tatjana Kolevska and Robert Robles and Flowers, {Christopher R.} and Robert Collins and DiBella, {Nicholas J.} and Steven Papish and Parameswaran Venugopal and Andrew Horodner and Amir Tabatabai and Julio Hajdenberg and Jaehong Park and Rachel Neuwirth and George Mulligan and Kaveri Suryanarayan and Esseltine, {Dixie Lee} and {De Vos}, Sven",
year = "2017",
month = "11",
day = "1",
doi = "10.1200/JCO.2017.73.2784",
language = "English (US)",
volume = "35",
pages = "3538--3546",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

Leonard, JP, Kolibaba, KS, Reeves, JA, Tulpule, A, Flinn, IW, Kolevska, T, Robles, R, Flowers, CR, Collins, R, DiBella, NJ, Papish, S, Venugopal, P, Horodner, A, Tabatabai, A, Hajdenberg, J, Park, J, Neuwirth, R, Mulligan, G, Suryanarayan, K, Esseltine, DL & De Vos, S 2017, 'Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma', Journal of Clinical Oncology, vol. 35, no. 31, pp. 3538-3546. https://doi.org/10.1200/JCO.2017.73.2784

Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. / Leonard, John P.; Kolibaba, Kathryn S.; Reeves, James A.; Tulpule, Anil; Flinn, Ian W.; Kolevska, Tatjana; Robles, Robert; Flowers, Christopher R.; Collins, Robert; DiBella, Nicholas J.; Papish, Steven; Venugopal, Parameswaran; Horodner, Andrew; Tabatabai, Amir; Hajdenberg, Julio; Park, Jaehong; Neuwirth, Rachel; Mulligan, George; Suryanarayan, Kaveri; Esseltine, Dixie Lee; De Vos, Sven.

In: Journal of Clinical Oncology, Vol. 35, No. 31, 01.11.2017, p. 3538-3546.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Randomized Phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma

AU - Leonard, John P.

AU - Kolibaba, Kathryn S.

AU - Reeves, James A.

AU - Tulpule, Anil

AU - Flinn, Ian W.

AU - Kolevska, Tatjana

AU - Robles, Robert

AU - Flowers, Christopher R.

AU - Collins, Robert

AU - DiBella, Nicholas J.

AU - Papish, Steven

AU - Venugopal, Parameswaran

AU - Horodner, Andrew

AU - Tabatabai, Amir

AU - Hajdenberg, Julio

AU - Park, Jaehong

AU - Neuwirth, Rachel

AU - Mulligan, George

AU - Suryanarayan, Kaveri

AU - Esseltine, Dixie Lee

AU - De Vos, Sven

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP (P = .611). Two-year PFS rateswere 77.6%with R-CHOP and 82.0%with VR-CHOP; they were 65.1% versus 72.4%in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade $ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.

AB - Purpose To evaluate the impact of the addition of bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). Patients and Methods After real-time determination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were randomly assigned (1:1; stratified by International Prognostic Index [IPI] score) to six 21-day cycles of standard R-CHOP alone or R-CHOP plus bortezomib 1.3 mg/m2 intravenously on days 1 and 4 (VR-CHOP). The primary end point, progression-free survival (PFS), was evaluated in 183 patients with centrally confirmed non-GCB DLBCL who received one or more doses of study drug (91 R-CHOP, 92 VR-CHOP). Results After a median follow-up of 34 months, with 25% (R-CHOP) and 18% (VR-CHOP) of patients having had PFS events, the hazard ratio (HR) for PFS was 0.73 (90% CI, 0.43 to 1.24) with VR-CHOP (P = .611). Two-year PFS rateswere 77.6%with R-CHOP and 82.0%with VR-CHOP; they were 65.1% versus 72.4%in patients with high-intermediate/high IPI (HR, 0.67; 90% CI, 0.34 to 1.29), and 90.0% versus 88.9% (HR, 0.85; 90% CI, 0.35 to 2.10) in patients with low/low-intermediate IPI. Overall response rate with R-CHOP and VR-CHOP was 98% and 96%, respectively. The overall survival HR was 0.75 (90% CI, 0.38 to 1.45); 2-year survival rates were 88.4% and 93.0%, respectively. In the safety population (100 R-CHOP and 101 VR-CHOP patients), grade $ 3 adverse events included neutropenia (53% v 49%), thrombocytopenia (13% v 29%), anemia (7% v 15%), leukopenia (26% v 25%), and neuropathy (1% v 5%). Conclusion Outcomes for newly diagnosed, prospectively enrolled patients with non-GCB DLBCL were more favorable than expected with R-CHOP and were not significantly improved by adding bortezomib.

UR - http://www.scopus.com/inward/record.url?scp=85032434494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032434494&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.73.2784

DO - 10.1200/JCO.2017.73.2784

M3 - Article

VL - 35

SP - 3538

EP - 3546

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -